Voronoi

310210.KQ

122.33 USD

-8.25

-6.32%

Overview

Last close

122.33 usd

Market cap

2.20B usd

52 week high

169.84 usd

52 week low

43.06 usd

Target price

180.39 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

430.1537

Price/Book Value

65.2547

Enterprise Value

2.33B usd

EV/Revenue

51.1462

EV/EBITDA

-15.8405

Key financials

Revenue TTM

5.10M usd

Gross Profit TTM

5.10M usd

EBITDA TTM

-31.98M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

71.08M usd

Net debt

9.01M usd

About

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was founded in 2015 and is based in Incheon, South Korea.